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Fatty acid oxidation in mitochondrial matrix is a major source of 
energy in muscle, especially when physiological energy demand is 
increased and exceeds what can be provided through glycolysis. 
Not surprisingly, a group of muscle disorders due to defects in this 
system usually leads to the development of acute rhabdomyolysis 
in conditions such as infection, fasting and prolonged exercise. 
This group includes β-oxidation cycle defects and deficiencies of 
carnitine  palmitoyltransferase  II  (CPTII)  and  very-long-chain 
acyl-CoA  dehydrogenase  (VLCAD).  Muscle  pathology  is  usu-
ally not very helpful for the diagnosis but immunohistochemistry 
may be useful for screening VLCAD deficiency. Another group 
of lipid dysmetablolism is lipid storage myopathy (LSM) that is 
pathologically characterized by increased lipid droplets both in 
number and size in muscle fibers. So far, causative genes have 
been identified in four different LSMs, comprising primary car-
nitine deficiency, multiple acyl-CoA dehydrogenase deficiency or 
glutaric aciduria type II, neutral lipid storage disease with ich-
thyosis, and neutral lipid storage disease with myopathy. Clini-
cally, the LSM patients show slowly progressive muscle weakness 
unlike the former group. Final diagnosis is usually made by spe-
cific biochemical assays with mutation analyses. As some effective 
drugs have been widely used and some promising therapies are 
under certified, comprehensive understanding of these diseases 
from clinical, pathological and molecular aspects would be of 
much help for the patients. 
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Introduction
Lipid consists of two types of molecules: fatty acid 
and its derivatives including triglycerides (TG), and ster-
ol-containing metabolites such as cholesterol. Fatty acids 
are catabolized through β-oxidation cycle in mitochon-
drial matrix and thus ATP is produced. Short- and medi-
um-chain fatty acids can enter cells and then mitochon-
dria by diffusion but long-chain fatty acids require fatty 
acid transporters at the plasma membrane and carnitine 
palmitoyltransferase (CPT) system at the mitochondrial 
membranes. 
Lipid dysmetabolism, involving intracellular TG ca-
tabolism, the transport of long-chain fatty acids and carni-
tine, or β-oxidation, often causes different extent of lipid 
accumulation in skeletal muscle fibers and in other organs. 
Among the disorders of lipid metabolism, primary carni-
tine deficiency (PCD), multiple acyl-coenzyme A dehy-
drogenase deficiency (MADD) and neutral lipid storage 
disease with ichthyosis (NLSDI) or myopathy (NLSDM) 
usually show markedly increased lipid droplets in muscle 
fibers which are ordinarily termed lipid storage myopathy 
(LSM). On the other hand, lipid storage could be mild or 
even absent in the defects of intramitochondrial fatty acid 
transport and β-oxidation. 
The phenotype of lipid metabolism disorders is het-
erogeneous but can generally be divided into two major 
categories (1), especially in late onset patients. Constant 
or progressive muscle weakness associated with or with-
out metabolic crisis, is often seen in LSM patients while 
recurrent rhabdomyolysis triggered by infections, fasting 
or vigorous exercise usually occur in the patients with 
disorders affecting intramitochondrial fatty acid transport 
and β-oxidation, such as deficiencies of carnitine palmi-
toyltransferase  II  (CPTII),  mitochondrial  trifunctional 
protein (MTP) and very-long-chain acyl-CoA dehydro-
genase (VLCAD). However, in infantile onset patients, 
the clinical manifestations are somehow similar among 
all  types  of  lipid  dysmetabolism,  including  hypotonia, 
hypoketotic  hypoglycemic  encephalopathy,  hepatome-
galy and cardiomyopathy. 
In this review, we would like to go through CPTII 
and VLCAD deficiencies briefly but mainly focus on four 
LSMs with known causative genes, PCD, MADD, NLS-
DI and NLSDM. 
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Carnitine palmitoyltransferase II 
deficiency (CPTII deficiency)
CPTII, located at the inner mitochondrial membrane, 
is  responsible  for  the  transfer  of  long-chain  acyl-CoA 
(Fig. 1), thus the defects in CPTII would apparently affect 
the access of long-chain acyl-CoA to β-oxidation. CPTII 
deficiency caused by the mutations in the CPT2 gene is 
the first inherited defect of fatty acid oxidation to be iden-
tified (2). Three clinical subtypes, neonatal, infantile and 
mild late-onset forms, have been described but muscular 
symptoms including recurrent rhabdomyolysis and mus-
cle pain after long-term exercise were mainly associated 
with the late-onset form (3). Infantile cases usually present 
recurrent attacks of acute liver failure with hypoketotic 
hypoglycemia, cardiomyopathy and sudden death while 
neonatal-onset patients demonstrate a more severe pheno-
type with dysmorphic features. There is a good correlation 
between genotype, metabolic dysfunction and phenotype 
as null or truncated mutations often cause absent enzyme 
activity and earlier-onset phenotype (2). A common muta-
tion, p.S113L, has been found in more than 50% of mu-
tant alleles in mild late-onset patients. 
Metabolic profiles in CPTII deficiency patients usu-
ally  show  increased  long-chain  acylcarnitines.  Creat-
ine  kinase  (CK)  level  is  markedly  elevated  after  pro-
longed fasting or exercise. Muscle pathology is typically 
characterized by nonspecific changes without increased 
lipid droplets. Therefore, enzymatic assay in leukocyte, 
cultured fibroblasts or biopsied muscles may be the most 
reliable diagnostic test, as well as the mutation analysis 
for CPT2. The treatment for CPTII deficiency is mainly 
dependent on restricting the diet and avoiding fasting. 
Long-chain fat –restricted diet with medium-chain trig-
lycerides (MCT) supplementation is recommended (4). 
Recently, bezafibrate, a commonly used hypolipidemic 
drug, has shown to restore the capacity for normal fatty 
acid oxidation in muscle cells from patients with a mild 
form of CPTII deficiency (5). Though one open-labeled 
pilot study was just reported to improve the oxidation rate 
of long-chain fatty acid and the physical activity of the 
CPTII patients (6), further clinical trials and prolonged 
clinical follow-up are necessary to confirm its efficacy. 
Very-long-chain acyl-coenzyme A 
dehydrogenase deficiency (VLCAD 
deficiency)
VLCAD  localizes  in  the  inner  mitochondrial 
membrane and catalyzes the long-chain fatty acyl-CoA 
which is just incorporated into mitochondrial matrix by 
CPTII. Therefore, VLCAD is immediately downstream 
to CPTII in long-chain fatty acyl-CoA oxidation pathway. 
Not surprisingly, the clinicopathological manifestations of 
VLCAD deficiency in myopathic or adult-onset form are 
very similar to CPTII deficiency which typically presents 
recurrent rhabdomyolysis triggered by exercise or fast-
ing. There are also early-onset patients showing mainly 
cardiac and hepatic involvement. The mutations in the 
ACADVL gene was first identified in 1995 (7) and a clear 
genotype-phenotype correlation has been reported (8). 
The diagnosis of VLCAD deficiency relies on the 
measurement  of  metabolic  profile,  showing  abnormal 
elevation  of  long-chain  acylcarnitines.  Muscle  pathol-
ogy usually reveals only nonspecific findings but some-
times  a  variable  degree  of  necrotic  and  regenerating 
changes in muscles fibers reflecting recent episodes of 
rhabdomyolysis. Lipid droplets are usually not increased. 
In addition, immunohistochemistry has demonstrated as 
an effective and useful diagnostic method to detect VL-
CAD deficiency (Fig. 2A) (9). The therapeutic strategy is 
also similar to CPTII deficiency. However, some reports 
showed MCT supplementation did not benefit the patients 
and even impaired hepatic lipid metabolism in VLCAD-
knockout mice (10, 11). And as well as CPTII deficiency, 
bezafibrate was also used to treat the cultured fibroblasts 
from VLCAD deficiency patient and demonstrated the in-
creases of both mRNA expression and protein level (12). 
Thus, further in vivo studies are needed to prove its ben-
efit in VLCAD deficiency. 
Figure 1. Scheme of selected metabolic pathways of 
lipid.  (OCTN2:  plasma  membrane  sodium-dependent 
carnitine transporter; TG: triglycerides; DG: diglycerides; 
ATGL: adipose triglyceride lipase; CGI-58: comparative 
gene  identification-58;  CPTI:  carnitine  palmitoyltrans-
ferase I; CACT: carnitine-acylcarnitine translocase; CPTII: 
carnitine palmitoyltransferase II; VLCAD: very long-chain 
acyl-CoA  dehydrogenase;  MTP:  mitochondrial  trifunc-
tional  protein;  SCAD/MCAD:  short-chain/medium-chain 
acyl-CoA dehydrogenases; ETF: electron-transfer flavo-
protein; ETFDH: ETF-dehydrogenase; Q: coenzyme Q; C: 
cytochrome c).Muscle lipid diseases
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Primary carnitine deficiency (PCD)
PCD, caused by impaired function of plasma mem-
brane sodium-dependent carnitine transporter (OCTN2), 
is possibly the second most frequent disorder affecting 
fatty acid oxidation following medium chain acyl-CoA 
dehydrogenase deficiency with the carrier frequency of 
about 1% (13). The function of OCTN2 is to transfer car-
nitine across the plasma membrane. As carnitine is es-
sential for the transfer of long-chain fatty acids from the 
cytoplasm to the mitochondrial matrix for following oxi-
dation (Fig. 1), the defect of OCTN2, leading to urinary 
loss of carnitine and the failure of intracellular accumula-
tion, would culminate in deficient fatty acid oxidation. 
PCD is an autosomal recessive disorder, caused by 
the mutations in SLC22A5 which encodes OCTN2 (14). 
The clinical manifestations of PCD are widely variable, 
ranging from asymptomatic feature, isolated cardiomy-
opathy to lethal metabolic decompensation. As mentioned 
above, the infantile onset patients with PCD principally 
present hypotonia, Reye-like syndrome and cardiomyop-
athy. However, the cardiomyopathy may develop solely 
or with a milder metabolic presentation during childhood 
or even older age (15). Since skeletal muscle uses fatty 
acid as a major energy source, muscle weakness can also 
be observed in PCD patients. Some patients, who have 
been asymptomatic for their whole life, may be identi-
fied because of their affected children or siblings (16, 17). 
There is no clear correlation between genotype and either 
clinical or biochemical phenotype yet reported, suggest-
ing that the wide phenotypic variability may be related 
to epigenetic or exogenous factors which exacerbate car-
nitine deficiency (18). Common blood tests may reveal 
increased levels of hepatic enzymes and CK. 
As for the diagnosis of PCD, the measurement of free 
carnitine and all acylcarnitine species is essential and both 
extremely low levels are indicative of PCD. Secondary 
carnitine deficiency should be carefully excluded which 
may show decreased free carnitine level but elevated spe-
cific species of acylcarnitine. However, as plasma carni-
tine level can occasionally be normal in PCD, carnitine 
transport study in fibroblasts may also be used to confirm 
the diagnosis. On muscle pathology, markedly increased 
lipid droplets in both number and size in muscle fibers 
are seen, especially in type 1 fibers (Fig. 2B). Ultrastruc-
tural study often shows that lipid droplets are present next 
to mitochondria which are usually enlarged but structur-
ally normal. Moreover, as PCD is caused by the defect 
of OCTN2, searching for the mutations in SLC22A5 is 
another way to establish the diagnosis of PCD. 
PCD patients are well responsive to carnitine supple-
mentation (100-400 mg/kg per day). Early carnitine therapy 
has been believed to prevent the occurrence of cardiomy-
opathy and other irreversible organ damage (18). In recent 
years, activation of peroxisome proliferator-activated re-
ceptor α (PPARα) has been proved to cause an up-regula-
tion of OCTN2, leading to an increase of intracellular car-
nitine concentration in animal models (19, 20). Therefore, 
PPARα  agonists may be potential candidates for treating 
PCD patients in addition to carnitine supplementation. 
Multiple acyl-coenzyme A 
dehydrogenase deficiency (MADD)
MADD, also known as glutaric aciduria type II, is 
caused  by  the  defects  in  electron  transfer  flavoprotein 
(ETF), ETF dehydrogenase (ETFDH) (also called ETF-
ubiquinone oxidoreductase), or an unidentified abnormal-
ity in flavin metabolism or transport. In mitochondria, ETF, 
which is located in the matrix, receives electron from sev-
Figure  2.  Muscle pathology. (H&E: hematoxylin-eosin) 
(A) Immunohistochemistry shows negative staining of VL-
CAD in the patient with VLCAD deficiency. (B) In PCD, lipid 
droplets are markedly increased in both number and size 
in muscle fibers, especially type 1 fibers. (C) In MADD, 
similar features of increased lipid accumulation are seen 
as those in PCD. (D) In NLSDM, except for increased lipid 
droplets, rimmed vacuoles are seen in muscle fibers.W-C. Liang, I. Nishino
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eral dehydrogenases involved in fatty acid oxidation. Elec-
trons are then transferred to ETFDH, located in the inner 
mitochondrial membrane, and subsequently, are passed to 
ubiquinone in the respiratory chain (Fig. 1). ETF, ETFDH, 
and most mitochondrial enzymes associated with electron 
transfer system are flavoproteins, which contain flavin ad-
enine  dinucleotide  prosthetic  groups  (FAD).  Therefore, 
defective ETF or ETFDH, disturbing the electron transfer, 
would finally result in accumulation of various intramito-
chondrial acyl-CoA esters, decrease of intramitochondrial 
flavin, and probable mitochondrial dysfunction. 
Homozygous or compound heterozygous mutations in 
ETFA, ETFB and ETFDH, which encode α– and β–subunits 
of ETF and ETFDH, respectively (21), have been identi-
fied in MADD patients. Importantly, ETFDH mutations 
were reported to be major causes of riboflavin-responsive 
MADD (RR-MADD) (22). About the same time, ETFDH 
mutations were also found to cause the myopathic form of 
coenzyme Q10 (CoQ10) deficiency (23). However, the rela-
tionships between riboflavin responsiveness, CoQ10 levels 
and ETFDH gene mutations are not well-defined. Intrigu-
ingly, a probable founder mutation, c.250G > A (p.A84T) 
in ETFDH, was recently reported in southern Chinese pop-
ulation with an estimated carrier frequency of about 0.8% 
in Taiwanese (24, 25). To date, all 20 reported MADD pa-
tients with ETFDH mutations from southern Chinese pop-
ulation harbor this mutation (25-27). Compared to Japan 
with more than 5 times population of Taiwan, the similar 
number of reported MADD patients with ETFDH muta-
tions indicates that the incidence of MADD may be much 
higher than previously estimated and many MADD pa-
tients may actually be underdiagnosed at least in Taiwan. 
The clinical phenotype of MADD is quite heterogene-
ous and has been classified as neonatal onset forms with or 
without congenital anomalies, and mild and/or later onset 
form. Patients with neonatal onset forms usually present 
with hypotonia, hepatomegaly, nonketotic hypoglycemia, 
metabolic acidosis and the patients usually died early in 
infancy. Later onset patients manifest proximal myopathy 
often with hepatomegaly and episodic metabolic crisis; 
these episodes can be lethal (28). Cardiomyopathy has al-
so been reported in both neonatal and later onset MADD 
patients (29). Though no clear genotype-phenotype cor-
relation for each gene has been described, there seems 
a tendency that the mutations in ETFA and ETFB cause 
neonatal  onset  forms  while  the  patients  with  ETFDH 
mutations often present the clinical course as later onset 
form (30, 31). However, the disease severity is correlated 
to not only the nature of the gene defect but also the cellu-
lar factors that may modulate the enzymatic activity (32). 
Mildly to moderately elevated CK levels are often found 
in routine biochemical test, especially during the episodes 
of metabolic decompensation. 
The key to diagnosis is the measurement of urinary 
organic  acid  profiles,  plasma  carnitine,  and  acylcarni-
tines. Urine organic acid analysis typically shows C5 to 
C10  dicarboxylic  aciduria  and  acylglycine  derivatives. 
Plasma free carnitine level is decreased but sometimes re-
tains normal in some cases. Blood acylcarnitine analysis 
usually displays elevated concentrations of mainly me-
dium- and long-chain acylcarnitines. In addition, reduced 
biochemical activities of other mitochondrial enzymes in-
cluding flavin-dependent and respiratory chain enzymes, 
have been reported (22, 33, 34) in MADD, though it is 
still unknown if this mitochondrial dysfunction is directly 
caused by ETFDH mutations or other factors. As the vari-
able clinical manifestations may not be correlated to the 
impression of MADD, increased lipid deposition in mus-
cles is sometimes the first sign guiding the subsequent bi-
ochemical studies for lipid dysmetabolism. Noteworthily, 
the biochemical assays occasionally show normal results 
between  each  episodes  of  metabolic  decompensation, 
thus mutation analyses of ETFA, ETFB and ETFDH may 
be the most confirmative diagnostic method for MADD. 
The characteristic features of muscle pathology are simi-
lar to those seen in PCD (Fig. 2C). 
Although the molecular mechanism of MADD is still 
unclear, riboflavin supplementation (100-400 mg/day) has 
been known to markedly improve the clinical symptoms 
and metabolic profiles of many MADD patients, particu-
larly with ETFDH mutations and later onset form, as men-
tioned previously. Several studies have shown that FAD, 
comprised  in  many  mitochondrial  enzymes  related  to 
electron transfer, may modulate the enzymatic phenotype 
of mutations in the electron transfer proteins. It has been 
observed that FAD level affects folding and maintenance 
of the native structure of these proteins and could improve 
their conformation and generate a more stable and active 
enzyme in vitro (35). Accordingly, riboflavin should be 
tried in all types of MADD patients. There is still a con-
troversy about the combination therapy with carnitine. It 
could be helpful when secondary carnitine deficiency is 
present. CoQ
10 supplementation has also been reported to 
improve muscle weakness in MADD patients with CoQ10 
deficiency (23),  together  with  riboflavin  use.  However, 
as the CoQ10 level is not always decreased in MADD pa-
tients (24), its supplementation should be considered only 
when secondary CoQ10 deficiency is present. 
Neutral lipid storage disease  
with ichthyosis (NLSDI)  
or myopathy (NLSDM)
Neutral lipid storage disease (NLSD) is a rare lipid 
storage disorder caused by defects in two TG-associated 
proteins, adipose triglyceride lipase (ATGL) and alpha/Muscle lipid diseases
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beta-hydrolase  domain-containing  protein  5  (ABHD5) 
(also  called  comparative  gene  identification-58  [CGI-
58)]). ATGL catalyzes TG and releases the first fatty acid 
from the glycerol backbone and CGI-58 activates ATGL 
and acylates lysophosphatidic acid. Activation of ATGL 
initiates the hydrolytic catabolism of cellular TG stores to 
glycerol and nonesterified fatty acids (Fig. 1). Therefore, 
dysfunction of these two proteins apparently would affect 
the degradation of TG, and then cause its accumulation. 
Mutations in alpha/beta-hydrolase domain-contain-
ing  protein  5  (ABHD5)  have  been  identified  to  cause 
NLSDI,  also  known  as  Chanarin-Dorfman  syndrome 
(CDS) (36).  However,  some  patients  present  atypical 
CDS features, with myopathy and cardiomyopathy but 
without ichthyosis and mutation in ABHD5. This pheno-
type was called NLSDM and further facilitated the dis-
covery of new causative gene, patatin-like phospholipase 
domain containing 2 (PNPLA2), encoding ATGL (37). So 
far, the mutations in ABHD5 have been reported to cause 
protein truncations but not absence, suggesting that the 
mutant protein is not completely deficient but function-
ally impaired (33). In NLSDM, almost all mutations in 
PNPLA2  are  located  on  C-terminal  region,  preserving 
the proposed active site of the enzyme. These truncated 
enzyme variants have later been shown impaired in their 
ability to bind to cellular lipid droplets in vitro (38). 
NLSD is characterized by systemic TG deposition 
in multiple tissues, including skin, muscle, liver, central 
nervous system, and blood leukocytes. Clinically, it is of-
ten present with ichthyosis, mild myopathy, hepatomega-
ly and, variably, ophthalmologic symptoms, neurosensory 
hearing loss, mental retardation and short stature (39-41). 
In NLSDI, the ichthyosis represents nonbullous congenital 
ichthyosiform erythroderma and the weakness is usually 
mild and predominant proximal. However, in NLSDM, 
no  ichthyosis  is  observed  and  the  slowly  progressive 
muscle involvement could be in both proximal and dis-
tal limbs, with a predominant distal weakness in some 
patients. Importantly, the cardiomyopathy is exclusively 
seen in almost half of the patients with NLSDM (41), but 
not NLSDI while neurosensory defects and mental retar-
dation are commonly seen in NLSDI but not NLSDM. 
CK level is usually mildly to moderately elevated. 
The detection of lipid accumulation in leukocytes, 
muscle fibers and fibroblasts is critical for the diagnosis 
of NLSD as the clinical manifestations of NLSD are in-
constant and the biochemical investigations for lipid dys-
metabolism usually do not show any abnormality. The 
intracytoplasmic lipid storage in leukocytes is visible on 
peripheral blood smear, which is called Jordan’s anoma-
ly. In skeletal muscles, increased lipid droplets could be 
observed even in presymptomatic period. Noteworthily, 
rimmed vacuoles in the muscles were reported in some 
NLSDM patients (Fig. 2D) (42, 43), suggesting a differ-
ent pathomechanism from other LSMs, which might be 
associated  with  membrane  phospholipid  abnormalities 
caused by decreased DG availability. 
So far, there is still no effective treatment in NLSD. 
The functions of ATGL and CGI-58 are still largely un-
known.  However,  the  production  of  the  mice  lacking 
ATGL has provided an opportunity to prompt the under-
standing of NSLDM (44), though unfortunately, the phe-
notype of CGI-58-deficient mice has not been reported 
yet. The elucidation of the biological role of CGI-58 in li-
pid dysmetabolism and further development of therapeu-
tic strategy may be dependent on more detailed genetic 
and clinical characterization of NSLDI patients and the 
establishment of appropriate animal models. 
Conclusions
Muscle lipid disease is phenotypically and genotypi-
cally heterogeneous. The detailed observation of clinical 
features combined with the distinct results of biochemical 
assays is required. In addition, mutation analyses are usually 
helpful for making the final diagnosis especially when clini-
cal phenotype and laboratory tests show indistinguishable 
and nonspecific findings. Prompt diagnosis is important for 
subsequent treatment of patients especially as carnitine and 
riboflavin have shown excellent efficacy in the patients with 
PCD and RR-MADD. Moreover, in many patients with li-
pid dysmetabolism, the causative genes remain unknown. 
Thus, to discover the novel causative genes and then further 
explore the pathomechanism would be important missions 
in the future studies on muscle lipid diseases. 
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